-
Horizon Pharma Tops EPS Estimates, Falls Short on Revenue
Monday, March 18, 2013 - 11:54am | 428Read More...Horizon Pharma (NASDAQ: HZNP) is down on Monday despite topping estimates during the fourth quarter and full year. The Deerfield, Illinois firm posted a loss of $0.34 per share, topping its Q4 2011 performance of a $0.97 loss. This figure also easily topped the Wall Street consensus of a $0.47...
-
Amarin and Horizon Pharma Higher Ahead of PDUFA Dates
Monday, July 23, 2012 - 3:06pm | 157Read More...Horizon Pharma (NASDAQ: HZNP) and Amarin (NASDAQ: AMRN) both have upcoming Prescription Drug User Fee Act dates on Thursday. PDUFA refers to the fees that the FDA collects from drug manufacturers and allocates towards a drug's review process. The FDA traditionally makes an effort to complete its...
-
Biotechs With Upcoming PDUFA Dates
Wednesday, July 18, 2012 - 3:09pm | 871Read More...On Tuesday, the FDA approved the second weight-loss drug in the last 13 years when it green-lighted Vivus' drug Qsymia. On Wednesday, VVUS shares have shot up more than 14 percent to $30.27. The approval of this drug and the excitement that it has created in the biotech investing community may...
